Table 2.

Prevalence of diabetes and 5‐y age‐adjusted cause‐specific survival by cancer site, sex, and race among SEER‐Medicare cancer patients 66+ y diagnosed in 2000‐2011

Cancer site	Race	Males			Females
		% with diabetes	5‐y age‐adjusted cause‐specific survival (%)	95% CI	% with diabetes	5‐y age‐adjusted cause‐specific survival (%)	95% CI
Bladder	White	24.4	78.6	77.6‐79.5	19.0	68.2	66.2‐70.0
	Black	31.8	71.3	66.6‐75.5	35.1	54.5	48.8‐59.8
Cervix	White	~	~	~	20.4	49.2	44.2‐54.0
	Black	~	~	~	28.5	43.3	35.2‐51.1
Colon/Rectum	White	24.0	61.8	60.8‐62.8	21.2	60.4	59.4‐61.3
	Black	29.6	53.9	50.8‐56.9	34.7	57.6	55.4‐59.8
Corpus/Uterus	White	~	~	~	24.2	72.0	70.7‐73.3
	Black	~	~	~	39.4	52.6	48.9‐56.1
Female Breast ER‐	White	~	~	~	18.7	71.0	69‐72.9
	Black	~	~	~	35.5	64.8	60.9‐68.5
Female Breast ER+	White	~	~	~	18.7	87.9	87.3‐88.5
	Black	~	~	~	36.5	80.9	78.9‐82.8
Hodgkin Lymphoma	White	25.0	54.6	46.8‐61.8	23.9	54.3	46.3‐61.6
	Black	28.3	72.4	34.6‐90.6	38.5	57.1	31.8‐76.0
Liver	White	44.5	10.0	8.6‐11.6	39.4	9.2	7.3‐11.3
	Black	33.9	5.5	2.1‐11.4	41.3	10.5	4.9‐18.5
Myeloma	White	23.1	39.7	36.5‐42.9	19.5	32.3	28.9‐35.8
	Black	30.4	46.7	39.4‐53.7	31.8	42.1	36.0‐48.0
Non‐Hodgkin Lymphoma	White	23.4	54.8	53.1‐56.4	19.7	55.4	53.7‐57.0
	Black	28.5	52.1	44.4‐59.2	34.4	51.1	45.5‐56.5
Ovary	White	~	~	~	17.8	20.4	18.6‐22.3
	Black	~	~	~	35.4	19.2	14.9‐23.8
Pancreas	White	36.9	3.9	3.3‐4.6	31.5	4.1	3.5‐4.7
	Black	37.3	4.0	2.1‐6.8	48.9	1.9	1.1‐3.2
Prostate	White	17.9	91.6	91.2‐91.9	~	~	~
	Black	25.7	91.0	90.1‐91.7	~	~	~
Stomach	White	26.9	24.4	22.4‐26.5	25.9	31.8	29.3‐34.3
	Black	27.3	22.7	17.7‐28.1	37.2	31.8	27.1‐36.6

CI, confidence interval; ER, estrogen receptor; SEER, Surveillance, Epidemiology, and End Results.